Invitrogen™ Dilpacimab Humanized Recombinant Human Monoclonal Antibody

Human Recombinant Monoclonal Antibody

Supplier:  Invitrogen™ MA542209

Catalog No. PIMA542209

Description

Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.

Dilpacimab is a biosimilar that targets DLL4. Delta-like ligand 4 (DLL4), also know as Delta-4, is a homologue of the Drosophila delta protein, and functions as a transmembrane bound ligand to the notch receptor Notch1. DLL4 is expressed in the vasculature and plays a critical role in vascular development. It is induced by vascular endothelial growth factor (VEGF), as a negative feedback regulator to regulate angiogenic sprouting and promote the formulation of a differentiated vascular network. DLL4 has been found to be strongly expressed in tumor vessels of clear-cell renal tumors and bladder cancer, and inhibition of DLL4 results in increased vascular proliferation but defective maturation. This in turn leads to a decrease in tumor growth, with no apparent toxicity.

Specifications

• Antigen: Dilpacimab Humanized
• Classification: Recombinant Monoclonal
• Conjugate: Unconjugated
• Gene Alias: ABT-165; PR-1283233
• Immunogen: Human DLL4/VEGFA.
• Quantity: 100 μg
• Primary or Secondary: Primary
• Content And Storage: -20°C, Avoid Freeze/Thaw Cycles
• Form: Liquid
• Target Molecule: Chemical

• Applications: ELISA, SDS-Page
• Concentration: 1 mg/mL
• Formulation: PBS with no preservative; pH 7.4
• Host Species: Human
• Purification Method: Protein A
• Regulatory Status: RUO
• Target Species: Human
• Product Type: Antibody
• Isotype: IgG1 κ